Skip to content
Zydus Wellness logo

Zydus Wellness

ZYDUSWELL NSE
₹448.05 −7.80 (−1.71%)
Market Cap
₹14,255 Cr
P/E
57.89
View as Markdown
MCP
Close 20 Nov 2026 ₹448.05 1Y −0.50 −0.11%
Start ₹448.55

Key Fundamentals

SmallcapFood ProductsFMCG

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
4.91%
Debt to Equity
0.54
EPS (TTM)
₹7.74
Book Value
₹185.69
Market Cap
₹14,255 Cr
P/E (TTM)
57.89
P/B
2.41
ROE
3.98%
Dividend Yield
0.26%
EBITDA
₹516 Cr
52W High
₹611.85
52W Low
₹367.55
Day Range
₹443.65 – ₹459.55
Volume
1,40,918

Peer Comparison

Fast Moving Consumer Goods › Food Products › Packaged Foods

Zydus Wellness peer comparison
1,325.0061.802,55,50242.851.09%73.20%84.10%25,5814,134
4,900.0044.201,18,02527.781.94%53.50%56.00%20,2862,681
Zydus Wellness (this company)
448.0557.8914,2552.410.26%3.98%4.91%5,013246
508.9548.4312,7617.180.26%17.80%22.00%2,949264
1,310.207.059,1421.191.29%19.00%33.00%20,6712,629
221.5043.096,8005.100.60%11.50%14.10%2,198158
265.8331.843,3146.170.19%9.64%11.70%1,694104
Median 7 companies508.9544.2012,7616.170.60%17.80%22.00%5,013264

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

51 Average

Data confidence 100/100

Category scores

Quality
51
Average
Returns, margins, earnings quality 22% weight
Valuation
31
Poor
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
38
Weak
Solvency, leverage, coverage 9% weight
Momentum
44
Weak
Trend strength, vol-adjusted 12% weight
Ownership
56
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Company is expected to give good quarter

Weaknesses

2
  • Company has a low return on equity of 5.09% over last 3 years.
  • Dividend payout has been low at 14.1% of profits over last 3 years

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1243
OscillatorsBullish243
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
35.36
Neutral
MACD (12,26,9)
−11.17
Bearish
SMA (50)
497.22
Bearish
SMA (200)
493.94
Bearish

As of

Analyst Rating

Based on 7 analysts
BUY86%

6 of 7 analysts rate Buy, 1 Hold, 0 Sell.

As of

BUY
6
86%
HOLD
1
14%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+25.86%
5Y+16.23%
3Y+20.66%
1Y+46.22%
TTM+73.68%

Net profit

Net profit growth by window
10Y+6.49%
5Y+10.61%
3Y−14.03%
1Y−43.23%
TTM−2.88%

Operating cash flow

Operating cash flow growth by window
10Y+9.64%
5Y−4.67%
3Y+34.93%
1Y−40.53%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−10.04 pp
5Y−5.55 pp
3Y−2.06 pp
1Y−1.15 pp
TTM−0.15 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹431 Cr
Mar 2018₹513 Cr
Mar 2019₹843 Cr
Mar 2020₹1,767 Cr
Mar 2021₹1,867 Cr
Mar 2022₹2,009 Cr
Mar 2023₹2,255 Cr
Mar 2024₹2,328 Cr
Mar 2025₹2,709 Cr
Mar 2026₹3,961 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹111 Cr
Mar 2018₹137 Cr
Mar 2019₹171 Cr
Mar 2020₹142 Cr
Mar 2021₹119 Cr
Mar 2022₹309 Cr
Mar 2023₹310 Cr
Mar 2024₹267 Cr
Mar 2025₹347 Cr
Mar 2026₹197 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹94.40 Cr +7.3% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 19 Nov 2026
AI opinion · based on fundamentals
Risk high

Zydus Wellness Ltd trades at ₹455.85 as of 2026-11-19 with a market cap of ₹14,503 crore. The company shows strong top-line momentum with 74% TTM sales growth and a 26% compounded sales CAGR over 10 years, but profitability has contracted with a -11% TTM profit decline, a PE of 58.9x, and ROE of just 3.38%.

Bull Case 7
  • TTM revenue growth of 74% indicates a sharp acceleration in top-line momentum, suggesting strong demand or successful new product traction
  • 10-year compounded sales CAGR of 26% reflects a long track record of consistent revenue expansion in the FMCG space
  • 5-year compounded sales CAGR of 16% and 3-year sales CAGR of 21% show sustained mid-to-high-teens revenue growth across multiple time horizons
  • Debt-to-equity ratio of 0.55 as of 2026-11-19 is relatively manageable, indicating the balance sheet is not overleveraged
  • Stock is trading at ₹455.85 versus a 52-week low of ₹367.55, having recovered roughly 24% from its bottom, suggesting price support at lower levels
  • 10-year stock CAGR of 10% shows the company has delivered reasonable long-term capital appreciation for patient holders
  • The company is expected to deliver a good upcoming quarter, which could serve as a near-term positive catalyst
Bear Case 8
  • TTM profit has declined 11% and the 3-year compounded profit CAGR is -10%, indicating a persistent and worsening erosion in earnings
  • PE ratio of 58.9x as of 2026-11-19 is expensive for a company with shrinking profits, implying the stock prices in significant growth that has not materialized on the bottom line
  • ROE stands at just 3.38% as of 2026-11-19, with a 3-year average of about 5% and last year at 4%, well below acceptable thresholds for an FMCG business
  • ROCE of 3.43% as of 2026-11-19 suggests poor capital efficiency, meaning the company is generating minimal returns on deployed capital
  • Dividend yield of only 0.26% and a payout ratio of just 14.1% of profits over the last 3 years offer negligible income to shareholders
  • 5-year compounded profit CAGR of -2% shows the revenue-to-profit conversion has been structurally weak over a half-decade horizon
  • Stock trades at ₹455.85, roughly 25% below its 52-week high of ₹611.85, reflecting significant downward pressure from peak levels
  • Price-to-book ratio of 2.46x combined with a 3.38% ROE implies the market is paying a premium for assets that generate subpar returns

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

22h ago

TL;DR: Zydus Wellness delivered a strong Q2FY27 with a decisive profitability turnaround — revenue up 73% and EBITDA nearly quadrupling — largely powered by the Comfort Click acquisition. Margins are expanding but remain modest at 7.6%, and the FSSAI label-claim notice bears monitoring as a minor regulatory risk. The stock has gained 12% YTD but sits below its 52-week high of ₹611.85. If integration-driven revenue momentum sustains and margins continue expanding, the trend tilts positive heading into H2FY27.

Positives 3
  • Q2 PAT turnaround, EBITDA 4x Nov 3

    Zydus Wellness swung to a consolidated net profit of ₹5.1 crore in Q2FY27 from a net loss of ₹52.8 crore YoY. EBITDA surged nearly 4x to ₹85.2 crore with margins expanding 400 bps to 7.6%.

  • Revenue surges 73% YoY Nov 3

    Consolidated revenue jumped 73.2% YoY to ₹1,126.6 crore from ₹650.5 crore, driven by the Comfort Click acquisition. Standalone net profit rose 53% YoY to ₹116 million.

  • Exceptional gain aids profitability Nov 3

    Q2FY27 included an exceptional gain of ₹7 crore versus an exceptional loss of ₹16 crore in the base quarter, providing meaningful support to the profitability turnaround.

Neutral 2
  • Independent director exits after term Nov 17

    Kulin S. Lalbhai ceased as Independent Director on November 17, 2026, after completing his second five-year term. This is a routine board succession event.

  • FSSAI notice on label claims Oct 23

    Zydus Wellness received an FSSAI notice on September 24 regarding product-label claims and responded on October 4, asserting claims are scientifically substantiated.

Quarterly Results

₹ Cr
ZYDUSWELL quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
440
403
783
841
493
462
913
861
651
965
1,485
1,437
1,127
Expenses
423
391
620
686
473
447
723
705
628
904
1,215
1,195
1,041
Operating Profit
16.8
12.7
162
155
19.6
14.8
190
156
23
61
270
242
85.5
OPM %
3.82%
3.15%
20.73%
18.47%
3.98%
3.2%
20.81%
18.07%
3.54%
6.32%
18.19%
16.82%
7.59%
Other Income
4.1
3.4
4
5
4
3.8
0.8
3
1.4
0.8
1.2
3.8
6.4
Interest
6.5
6.3
6.1
3.6
0.9
3.3
4.2
2.5
15.7
41.2
38.7
26.3
27.2
Depreciation
5.8
6.1
5.7
5.1
4.9
5.2
13.2
10.8
25.1
55.5
55.3
57.1
57.1
Exceptional Items
—
—
—
—
5.9
—
—
—
−34.2
−6.6
—
—
—
PBT
8.6
3.7
154
152
23.7
10.1
173
145
−50.6
−41.5
177
162
7.6
Tax %
31.4%
91.89%
2.66%
2.57%
11.81%
36.63%
0.87%
11.98%
4.35%
−3.86%
8.63%
26.65%
32.89%
Net Profit
5.9
0.3
150
148
20.9
6.4
172
128
−52.8
−39.9
162
119
5.1
EPS (₹)
0.19
0.01
4.72
4.64
0.66
0.20
5.40
4.02
−1.66
−1.25
5.09
3.74
0.16
YoY Sales growth
2.52
−3.17
9.76
19.78
12.05
14.56
16.68
2.37
31.97
109
62.6
66.92
73.19

Profit & Loss

₹ Cr
ZYDUSWELL profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
431
397
431
513
843
1,767
1,867
2,009
2,255
2,328
2,709
3,961
5,013
Expenses
331
305
331
387
658
1,446
1,522
1,664
1,918
2,020
2,329
3,451
4,355
Operating Profit
100
91
99
125
185
321
344
345
337
308
380
510
658
OPM %
23%
23%
23%
24%
22%
18%
18%
17%
15%
13%
14%
13%
13%
Other Income
28
32
32
35
28
10.71
8.94
10
4.86
0
13.6
6.4
6
Interest
0
0
1
2
30
140
84
26
16
24
12
98
133
Depreciation
8
7
7
9
13
26
25
24
25
24
28
147
225
Exceptional Items
—
—
—
—
—
−44.2
−132
—
−10.05
—
5.9
−40.8
—
PBT
120
117
124
150
171
121
112
306
291
260
359
230
306
Tax %
7%
10%
10%
9%
0%
−17%
−6%
−1%
−7%
−3%
3%
14%
—
Net Profit
111
105
111
137
171
142
119
309
310
267
347
197
246
EPS (₹)
5.58
5.28
5.58
6.85
5.87
4.92
3.73
9.71
9.75
8.39
10.90
6.20
7.74
Div. Payout %
22%
25%
23%
23%
17%
20%
27%
10%
10%
12%
11%
19%
—
Sales growth
7
−8
9
19
64
110
6
8
12
3
16
46
74

Balance Sheet

₹ Cr
ZYDUSWELL balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
39
39
39
39
58
58
64
64
64
64
64
64
64
Reserves
367
439
518
652
3,329
3,403
4,504
4,780
5,059
5,294
5,608
5,762
5,844
Borrowings
0
0
25
25
1,569
1,519
550
387
297
329
188
3,203
3,167
Other Liabilities
102
89
100
112
503
610
548
461
413
462
582
1,161
1,277
Total Liabilities
508
568
682
829
5,459
5,590
5,666
5,692
5,833
6,148
6,442
10,190
10,352
Fixed Assets
84
82
103
104
4,567
4,674
4,667
4,710
4,732
4,708
5,125
8,596
8,602
CWIP
0
0
0
0
10
4
4
12
13
10
15
23
18
Investments
0
94
30
148
46
110
0
27
70
78
36
5
223
Other Assets
423
391
550
577
835
802
995
943
1,018
1,354
1,266
1,566
1,509
Total Assets
508
568
682
829
5,459
5,590
5,666
5,692
5,833
6,148
6,442
10,190
10,352

Cash Flow

₹ Cr
ZYDUSWELL cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
69
90
77
69
149
259
287
237
92
246
380
226
Investing
29
−28
−72
−59
−4,092
−17
−10
−59
−85
−178
−207
−2,881
Financing
−27
−58
−6
−2
4,052
−260
−216
−234
−138
−26
−186
2,698
Net Cash Flow
71
4
−1
8
109
−18
60
−56
−132
43
−13
44
Free Cash Flow
72
86
46
61
132
235
269
162
47
220
315
126
CFO/EBITDA
80
114
86
64
115
81
83
70
28
81
99
50

Ratios

ZYDUSWELL financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
1
3
3
6
42
24
18
26
34
44
49
35
Inventory Days
76
73
127
113
393
168
158
135
146
150
148
178
Days Payable
146
191
264
254
662
289
189
136
100
116
122
107
Cash Conversion Cycle
−69
−116
−134
−135
−227
−97
−13
25
80
78
75
106
Working Capital Days
−37
−38
−57
−26
−26
−7
−35
−27
17
20
34
48
ROCE %
32%
26%
23%
22%
7%
6%
6%
6%
6%
5%
6%
5%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Zydus Wellness insights

77 extracted metrics across FY09–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 69.64%
  • DIIs 19.39%
  • Public 5.73%
  • FIIs 3.56%
  • Others 1.67%

No promoter shares pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Zydus Wellness

What does Zydus Wellness Ltd do?
Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite.
Where is Zydus Wellness Ltd (ZYDUSWELL) listed?
Zydus Wellness Ltd trades as ZYDUSWELL on the NSE and under code 531335 on the BSE.
Which sector does Zydus Wellness Ltd belong to?
Zydus Wellness Ltd is classified under the Fast Moving Consumer Goods sector, in the Food Products industry.
What is the market capitalisation of Zydus Wellness Ltd?
Zydus Wellness Ltd has a market capitalisation of ₹14,255 Cr as of 20 Nov 2026, which places it in the Smallcap band.
What is the PE ratio of Zydus Wellness Ltd?
Zydus Wellness Ltd trades at a PE ratio of 57.89 as of 20 Nov 2026, on earnings per share of ₹7.74, against a book value of ₹185.69 per share.
What is the 52-week high and low of Zydus Wellness Ltd?
Over the last 52 weeks Zydus Wellness Ltd has traded between ₹367.55 and ₹611.85 as of 20 Nov 2026.
Does Zydus Wellness Ltd pay dividends?
Zydus Wellness Ltd has a dividend yield of 0.26%.
What is the Return on Equity (ROE) of Zydus Wellness Ltd?
Zydus Wellness Ltd reported a return on equity of 3.98%. Its debt-to-equity ratio is 0.54.

Company Information

Zydus Wellness operates as an integrated consumer Company with business encompassing the entire value chain in the development, production, marketing and distribution of health and wellness products. The product portfolio of the Company includes brands like Sugar free, Everyuth and Nutralite.

CEO Mr. Tarun G. Arora
Employees 1,247
Listed 13 Nov 2009
Face Value ₹2
Shares Outstanding 31,81,60,720

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ZYDUSWELL.md for Zydus Wellness Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More